MacroGenics - About the company
MacroGenics is a public company based in Rockville (United States), founded in 2000. It operates as a Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease. MacroGenics has raised $126M in funding from Ventures West and Nextech Venture. The company has 3141 active competitors, including 1095 funded and 748 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and BeiGene.
Company Details
Developer of novel biologics for the treatment of autoimmune disorders, cancer, and infectious disease. The company is developing immune-based products, including monoclonal antibodies and vaccines to prevent infections in healthy individuals. The company’s Fc engineering technology enables to the improvement of antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. Its lead candidate for cancer is Margetuximab, which is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2. HER2 is expressed by tumor cells in the breast, gastroesophageal, bladder, and other forms of solid tumor cancers, making it a key marker for biologic therapy.
- Website
- Social
Key Metrics
Founded Year
2000
Location
Rockville, United States
Stage
Public
Total Funding
in 10 rounds
Latest Funding Round
Investors
Ranked
34th among 3141 active competitors
Annual Revenue
as on Dec 31, 2022
Employee Count
as on Dec 31, 2023
Similar Companies
Exit Details
Public
Legal entities associated with MacroGenics
MacroGenics is associated with 3 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Aug 13, 2000 | $152M (as on Dec 31, 2022) | 149 | 219 | |
Dec 31, 1999 | - | 413 | 155 | |
Dec 26, 999 | - | 755 | 840 |
Get your free copy of MacroGenics's company profile
MacroGenics's funding and investors
MacroGenics has raised a total funding of $126M over 10 rounds. Its first funding round was on Sep 25, 2001. Its latest funding round was a Post IPO round on Mar 20, 2019 for an undisclosed amount. 1 investor participated in its latest round, which include InterWest Partners, Tekla Capital Management, TPG and Alta Partners.
MacroGenics has 30 institutional investors including Ventures West, Nextech Venture and InterWest Partners.
Here is the list of recent funding rounds of MacroGenics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Mar 20, 2019 | Undisclosed | Post IPO | 9204845 | 7063340 | |
Jan 28, 2011 | $12M | Series D | 3609849 | 5334153 | - |
Jul 15, 2010 | $9.8M | Grant (prize money) | 6790294 | 2585618 |
Access funding benchmarks and valuations. Sign up today!View details of MacroGenics's funding rounds and investors
MacroGenics's founders and board of directors
MacroGenics's employee count trend
MacroGenics has 339 employees as of Dec 23. The total employee count is 5.0% lower than what it was in Dec 22. Here is MacroGenics's employee count trend over the years:
Uncover MacroGenics's growth story! Sign up today!MacroGenics's Competitors and alternates
Top competitors of MacroGenics include Jazz Pharmaceuticals, Moderna and BeiGene. Here is the list of Top 10 competitors of MacroGenics, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of therapeutics for cancer and neurological disorders | $265M | InterWest Partners, Investor Growth CapitalÌý&²¹³¾±è;Ìý | 85/100 |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | Flagship Pioneering, WellingtonÌý&²¹³¾±è;Ìý | 85/100 |
3rd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | T. Rowe Price, TemasekÌý&²¹³¾±è;Ìý | 84/100 |
4th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | Vivo Capital, HBM PartnersÌý&²¹³¾±è;Ìý | 82/100 |
5th | Recursion 2013, United States, Public | R&D based company focused on manufacturing of drugs for multiple therapeutic areas | $452M | HTIF, Menlo VenturesÌý&²¹³¾±è;Ìý | 81/100 |
6th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | Tekla Capital Management, Ridgeback Capital ManagementÌý&²¹³¾±è;Ìý | 78/100 |
7th |  Revolution Medicines 2014, Redwood City (United States), Public | Developer of therapies for treating cancer | $181M | Vivo Capital, DeerfieldÌý&²¹³¾±è;Ìý | 78/100 |
8th | Blueprint Medicines 2008, Cambridge (United States), Public | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | Ridgeback Capital Management, Foresite CapitalÌý&²¹³¾±è;Ìý | 76/100 |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | Aisling Capital, Frazier Healthcare PartnersÌý&²¹³¾±è;Ìý | 76/100 |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | Roche, Perceptive AdvisorsÌý&²¹³¾±è;Ìý | 75/100 |
34th | 2000, Rockville (United States), Public | Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | InterWest Partners, Tekla Capital ManagementÌý&²¹³¾±è;Ìý | 66/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on MacroGenics's competitors? Click to see the top ones
MacroGenics's Investments and acquisitions
MacroGenics has made no investments or acquisitions yet.
Reports related to MacroGenics
Here is the latest report on MacroGenics's sector:
View
News related to MacroGenics
Media has covered MacroGenics for a total of 112 events in the last 1 year, 9 of them have been about company updates and 2 about partnerships.
•
GlobeNewswire•Mar 21, 2025•MacroGenics
•
Clinical Trials Arena•Mar 21, 2025•MacroGenics
•
•
GlobeNewswire•Nov 06, 2024•MacroGenics
•
Seeking Alpha•Oct 30, 2024•MacroGenics
•
Benzinga•Oct 30, 2024•MacroGenics
•
•
•
•
Benzinga•Sep 24, 2024•, MacroGenics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about MacroGenics
When was MacroGenics founded?
MacroGenics was founded in 2000.Where is MacroGenics located?
MacroGenics is located in Rockville, United States.When was the latest funding round of MacroGenics?
MacroGenics's latest funding round was on Mar 20, 2019.What is the annual revenue of MacroGenics?
Annual revenue of MacroGenics is $152M as on Dec 31, 2022.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- Cockrell Hard Cider - Puyallup based, 2012 founded, Funding Raised company
- FreetimeMed - Rochester based, 1990 founded, Unfunded company
- Blida 2 Lounici Ali University - Blida based, 2013 founded, Funding Raised company
- Sailwiz - Madrid based, 2017 founded, Funding Raised company
- Startyourplace - Paris based, 2012 founded, Funding Raised company
- The Nation Light - India based, Unfunded company
